Opus Genetics Inc

Opus Genetics reports promising Phase 1/2 BEST1 gene‑therapy results and FDA acceptance of a new phentolamine eye solution for presbyopia, boosting its vision‑therapy pipeline.

Opus Genetics, a clinical-stage biopharmaceutical company, is dedicated to developing innovative ophthalmic therapies and making a lasting impact in the biotechnology sector.

Opus Genetics Inc. is advancing its gene therapy programs for inherited retinal diseases, showcasing promising results and positioning itself as a significant player in the biotechnology sector.